Brokerages Set Paragon 28, Inc. (NYSE:FNA) Target Price at $14.20

Shares of Paragon 28, Inc. (NYSE:FNA) have been given an average recommendation of “Hold” by the six analysts that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $14.20.

FNA has been the topic of a number of recent analyst reports. William Blair cut Paragon 28 from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 29th. Needham & Company LLC reissued a “hold” rating and issued a $13.00 price objective on shares of Paragon 28 in a report on Wednesday, January 29th. Canaccord Genuity Group set a $13.00 price objective on Paragon 28 in a report on Wednesday, January 29th. Finally, Stephens reissued an “equal weight” rating and issued a $13.00 price objective (down previously from $14.00) on shares of Paragon 28 in a report on Thursday, January 30th.

Paragon 28 Trading Down 0.1 %

NYSE FNA opened at $12.98 on Friday. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -17.53 and a beta of 1.54. Paragon 28 has a one year low of $4.65 and a one year high of $13.13. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.50 and a quick ratio of 1.60. The business’s fifty day moving average is $11.79 and its 200-day moving average is $9.16.

Insider Activity

In other Paragon 28 news, major shareholder Mvm Partners, Llc sold 20,136 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $11.63, for a total value of $234,181.68. Following the sale, the insider now directly owns 10,366,009 shares in the company, valued at $120,556,684.67. This represents a 0.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 65,387 shares of company stock worth $733,197 over the last ninety days. Company insiders own 15.32% of the company’s stock.

Institutional Investors Weigh In On Paragon 28

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in Paragon 28 by 2,141.7% during the third quarter. JPMorgan Chase & Co. now owns 784,878 shares of the company’s stock valued at $5,243,000 after buying an additional 749,865 shares during the period. Vanguard Group Inc. boosted its stake in Paragon 28 by 17.9% during the fourth quarter. Vanguard Group Inc. now owns 2,809,109 shares of the company’s stock valued at $29,018,000 after buying an additional 425,983 shares during the period. First Light Asset Management LLC boosted its stake in Paragon 28 by 4.2% during the fourth quarter. First Light Asset Management LLC now owns 10,580,467 shares of the company’s stock valued at $109,296,000 after buying an additional 425,824 shares during the period. Millennium Management LLC bought a new stake in Paragon 28 during the fourth quarter valued at $3,598,000. Finally, Stonepine Capital Management LLC bought a new stake in Paragon 28 during the third quarter valued at $766,000. Hedge funds and other institutional investors own 63.57% of the company’s stock.

About Paragon 28

Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.